Hologic partners with Bayer on mammography imaging

Photo | Grant Welker Hologic's Marlborough headquarters

Write a Comment

By Isabel Tehan

Marlborough-based Hologic, a medical technology firm specializing in women’s health, has entered into a partnership with international pharmaceutical firm Bayer to provide enhanced imaging mammogram services.

The contrast-enhanced mammography solution combines digital mammograms with administration of a contrast agent, enabling more accurate diagnosis for a relatively lower cost, according to a Thursday press release from Hologic.

The partnership will combine Hologic’s mammogram technologies with Bayer’s injection system. It will be available in regions across Europe, Canada, and the Asia-Pacific area.

“Over the past several years, we’ve seen an increased interest in contrast-enhanced mammography as an additional diagnostic modality. Our partnership with Bayer will enable clinicians around the world to offer CEM as part of the breast cancer diagnostic workflow,” Tanja Brycker, vice president, strategic development, breast and skeletal health and GYN solutions at Hologic, said in the press release.

Financial terms for the partnership were not disclosed. Hologic, which quickly ramped up testing options during the COVID-19 pandemic, leading to a boom in revenue, is recovering from a drop in revenue as demand for tests has decreased.

Additionally, Hologic has added a new member to its board of directors, expanding the board to 10 members. Nanaz Mohtashami is managing director at Russell Reynolds Associates, a Boston executive search firm. She lead’s the firm’s global medical technology, devices, and diagnostics practice, according to a Friday press release.

“Her exceptional background in both global strategy and deep experience in the broader healthcare sector, combined with her strong team orientation, make her yet another strong addition to our board,” Steve MacMillan, Hologic’s chairman, president and CEO, said in the press release.